Search Result

Results for "

peritonitis

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (3) Antibiotic (10) Apoptosis (2) Bacterial (12) Beta-lactamase (6) Btk (1) Caspase (3) CCR (1) CDK (2) Cytochrome P450 (2) DNA/RNA Synthesis (4) ERK (1) Glutathione Peroxidase (1) Histamine Receptor (2) Interleukin Related (4) IRAK (1) Lipoxygenase (1) Melanocortin Receptor (1) NEKs (1) NF-κB (3) NOD-like Receptor (NLR) (8) Nucleoside Antimetabolite/Analog (2) p38 MAPK (2) PGE synthase (1) PI3K (3) PROTACs (1) RIP kinase (3) SARS-CoV (2) TGF-β Receptor (2) Thrombin (1) TRP Channel (1) VAP-1 (1) Vasopressin Receptor (1)
By Research Areas:	Cancer (7) Cardiovascular Disease (2) Endocrinology (1) Infection (14) Inflammation/Immunology (30) Neurological Disease (1)

By Targets:

Akt (3)

Antibiotic (10)

Apoptosis (2)

Bacterial (12)

Beta-lactamase (6)

Btk (1)

Caspase (3)

CCR (1)

CDK (2)

Cytochrome P450 (2)

DNA/RNA Synthesis (4)

ERK (1)

Glutathione Peroxidase (1)

Histamine Receptor (2)

Interleukin Related (4)

IRAK (1)

Lipoxygenase (1)

Melanocortin Receptor (1)

NEKs (1)

NF-κB (3)

NOD-like Receptor (NLR) (8)

Nucleoside Antimetabolite/Analog (2)

p38 MAPK (2)

PGE synthase (1)

PI3K (3)

PROTACs (1)

RIP kinase (3)

SARS-CoV (2)

TGF-β Receptor (2)

Thrombin (1)

TRP Channel (1)

VAP-1 (1)

Vasopressin Receptor (1)

By Research Areas:

Cancer (7)

Cardiovascular Disease (2)

Endocrinology (1)

Infection (14)

Inflammation/Immunology (30)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-163159

NP3-562	NOD-like Receptor (NLR)	Inflammation/Immunology
NP3-562 is a potent, orally active, tricyclic NLRP3 Inhibitor, with an IC₅₀ of 214 nM. NP3-562 (30 mg/kg, p.o.) inhibits IL-1β release in a mouse acute peritonitis model .

HY-P5535

Invopressin OCE-205	Vasopressin Receptor	Inflammation/Immunology
Invopressin (Compound 42) is a vasopressin V1A receptor partial agonist (EC₅₀: 1.0 nM). Invopressin can be used for research of cirrhosis, including bacterial peritonitis, HRS2 and refractory ascites .

HY-103586

GS-441524 Maximum Cited Publications 25 Publications Verification	DNA/RNA Synthesis SARS-CoV	Infection
GS-441524, predominant metabolite of Remdesivir and superior to Remdesivir against Covid-19 , shows comparable efficacy in cell-based models of primary human lung and cat cells infected with coronavirus. GS-441524 could strongly inhibits feline infectious peritonitis virus (FIPV), with an EC₅₀ of 0.78 μM .

HY-P10721

Plectasin	Antibiotic Bacterial	Infection
Plectasin is a peptide antibiotic derived from saprophytic fungi. Plectasin can kill pneumococcus in vitro. Plectasin can alleviate experimental peritonitis and pneumonia caused by pneumococcus in mice .

HY-103586A

GS-441524 hydrochloride	DNA/RNA Synthesis SARS-CoV	Infection
GS-441524 hydrochloride, predominant metabolite of Remdesivir and superior to Remdesivir against Covid-19 , shows comparable efficacy in cell-based models of primary human lung and cat cells infected with coronavirus. GS-441524 hydrochloride could strongly inhibits feline infectious peritonitis virus (FIPV), with an EC₅₀ of 0.78 μM .

HY-158111

NLRP3-IN-34	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-34 (Compound T10) is an inhibitor for NLRP3 inflammasome. NLRP3-IN-34 inhibits ROS production, NLRP3 inflammasome-dependent IL-1β production (IC₅₀ is 0.48 μM in cells J774A.1), and inhibits pyroptosis. NLRP3-IN-34 exhibits anti-inflammatory activity against DSS-induced peritonitis .

HY-161620

DW18134	IRAK	Inflammation/Immunology
DW18134 is an inhibitor for interleukin receptor-associated kinase 4 (IRAK 4) with an IC₅₀ of 11.2 nM. DW18134 inhibits phosphorylation of IRAK4 and IKK, downregulates the secretion of TNF-α and IL-6. DW18134 attenuates the Lipopolysaccharides (HY-D1056)-induced peritonitis and DSS-induced colitis in mouse models, and protects the intestinal barrier function .

HY-174270

NLRP3-IN-79	NOD-like Receptor (NLR) NEKs	Inflammation/Immunology
NLRP3-IN-79 (Compound B6) is a selective NLRP3 inflammasome inhibitor with an IC₅₀ value of 10.69 nM. NLRP3-IN-79 blocks the assembly of the NLRP3 inflammasome by disrupting the NEK7-NLRP3 interaction. NLRP3-IN-79 is promising for research of NLRP3-driven inflammatory diseases such as systemic inflammation, peritonitis, and colitis .

HY-10109A

AS-605240 potassium	PI3K Akt	Inflammation/Immunology
AS-605240 (potassium) is an orally active PI3Kγ inhibitor (IC₅₀: 8 nM; K_i: 7.8 nM). AS-605240 (potassium) inhibits MCP-1- and CSF1-induced PKB phosphorylation (IC₅₀ values are 0.181 and 0.550 µM, respectively). AS-605240 (potassium) reduces neutrophil recruitment in RANTES (CCL5)- and thioglycolate-induced peritonitis mouse models (EC₅₀ values are 9.1 and 10 mg/kg, respectively). AS-605240 (potassium) ameliorates αCII-IA-induced arthritis in mice .

HY-170835

NDM-1 inhibitor-7	Beta-lactamase Bacterial	Infection Inflammation/Immunology
NDM-1 inhibitor-7 (Compound A8) is a NDM-1 inhibitor, with IC₅₀ of 10.284 μM. NDM-1 inhibitor-7 restores the ability of MEM to penetrate the cell wall of gram-negative bacteria. NDM-1 inhibitor-7 effectively restores the antibacterial activity of MEM against NDM-1-positive Escherichia coli. NDM-1 inhibitor-7 demonstrates strong efficacy in both the Galleria mellonella infection model and murine peritonitis infection model .

HY-147301B

Resomelagon methanesulfonate AP1189 methanesulfonate	Melanocortin Receptor ERK	Inflammation/Immunology
Resomelagon methanesulfonate (AP1189 methanesulfonate) is the methanesulfonate salt form of Resomelagon (HY-147301). Resomelagon methanesulfonate is an orally active melanocortin receptor (MR) agonist. Resomelagon methanesulfonate induces ERK1/2 phosphorylation and Ca ²⁺ mobilization. Resomelagon methanesulfonate exhibits anti-inflammatory activity in mouse peritonitis and peritonitis model. Resomelagon methanesulfonate can be used for obesity and chronic inflammation research .

HY-B0977R

Dicloxacillin (Sodium hydrate) (Standard)	Bacterial Antibiotic	Infection Inflammation/Immunology
Dicloxacillin (Sodium hydrate) (Standard) is the analytical standard of Dicloxacillin (Sodium hydrate). This product is intended for research and analytical applications. Dicloxacillin Sodium hydrate (Dicloxacillin sodium salt monohydrate) is a narrow-spectrum β-Lactam antibiotic of the penicillin class, is used to treat infections caused by susceptible Gram-positive bacteria, active against beta-lactamase-producing organisms such as Staphylococcus aureus .

HY-B0977

Dicloxacillin Sodium hydrate 2 Publications Verification Dicloxacillin sodium salt monohydrate	Bacterial Antibiotic	Infection Inflammation/Immunology
Dicloxacillin Sodium hydrate (Dicloxacillin sodium salt monohydrate) is a narrow-spectrum β-Lactam antibiotic of the penicillin class, is used to treat infections caused by susceptible Gram-positive bacteria, active against beta-lactamase-producing organisms such as Staphylococcus aureus .

HY-14364

A-987306	Histamine Receptor	Inflammation/Immunology
A-987306 is a potent and oral bioavailable histamine H₄ antagonist, with K_is of 3.4 nM and 5.8 nM for rat H₄, and human H₄. A-987306 shows anti-inflammatory activity in mice peritonitis model .

HY-125650

Pseudouridimycin 1 Publications Verification PUM	Antibiotic DNA/RNA Synthesis Bacterial Nucleoside Antimetabolite/Analog	Infection
Pseudouridimycin (PUM) is an antibiotic that selectively inhibits bacterial RNA polymerase (RNAP), with an IC₅₀ of about 0.1 μM and MICs of 4-6 μg/mL. Pseudouridimycin is a C-nucleoside analogue that's effective against both Gram-negative and Gram-positive bacteria. Pseudouridimycin inhibits bacterial growth in vitro and shows activity in a mouse model of purulent streptococcal peritonitis .

HY-125650A

Pseudouridimycin TFA PUM TFA	Antibiotic DNA/RNA Synthesis Bacterial Nucleoside Antimetabolite/Analog	Infection
Pseudouridimycin (PUM) TFA is an antibiotic that selectively inhibits bacterial RNA polymerase (RNAP), with an IC₅₀ of about 0.1 μM and MICs of 4-6 μg/mL. Pseudouridimycin TFA is a C-nucleoside analogue that's effective against both Gram-negative and Gram-positive bacteria. Pseudouridimycin TFA inhibits bacterial growth in vitro and shows activity in a mouse model of purulent streptococcal peritonitis .

HY-155782

Zharp2-1	RIP kinase	Inflammation/Immunology
Zharp2-1 is an oral effective RIPK2 inhibitor, highly associated with inflammatory bowel disease (IBD). Zharp2-1 blocker muramyl dipeptide (MDP) induces growth of mononuclear cells and induces inflammatory cell factor infection. Zharp2-1 attenuates MDP-induced small inguinal peritonitis, or ameliorates by DNBS-induced large inguinal conjunctivitis .

HY-162846

NLRP3-IN-44	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-44 (compound P33) is a potent and orally active (approximately 62%) inhibitor of NLRP3, with the K_d of 17.5 nM. NLRP3-IN-44 plays an important for studying NLRP3 inflammasome-mediated diseases .

HY-13508

JNJ-7777120 1 Publications Verification	Histamine Receptor	Inflammation/Immunology
JNJ-7777120 is a potent and selective histamine H₄ receptor antagonist (K_i=4.5 nM). JNJ-7777120 effectively blocks histamine-induced migration of mouse tracheal mast cells from connective tissue to epithelial cells. JNJ-7777120 also significantly blocks neutrophil infiltration in a mouse Zymosan-induced peritonitis model. JNJ-7777120 has a good potential to study antipruritic and anti-inflammatory .

HY-149391

PROTAC BTK Degrader-6	PROTACs Btk	Inflammation/Immunology
PROTAC BTK Degrader-6 (Compound 15) is a PROTAC BTK degrader (DC₅₀: 3.18 nM. PROTAC BTK Degrader-6 has anti-inflammatory activity, inhibits NF-κB activation, and inhibits the expression of pro-inflammatory cytokines (e.g. IL-1β, IL-6) .

HY-125527A

17(R)-Resolvin D1 17(R)-RvD1; AT-RvD1	TRP Channel	Inflammation/Immunology
17R-Resolvin D1 (17R-RvD1; AT-RvD1) is an aspirin-triggered epimer of Resolvin D1, which exhibits anti-inflammatory activity in mice and human PMNs cells . 17R-Resolvin D1 specificially inhibits TRPV3 with an IC₅₀ of 398 nM and exhibits peripheral anti-nociceptive efficacy .

HY-170233

NLRP3-IN-75	NOD-like Receptor (NLR) Interleukin Related NF-κB	Inflammation/Immunology
NLRP3-IN-75 is an orally active NLRP3 inhibitor. NLRP3-IN-75 suppresses IL-1β secretion (IC₅₀ = 23 nM). NLRP3-IN-75 selectively inhibits NLRP3 activation by disrupting inflammasome assembly without affecting NLRC4 or AIM2 inflammasomes. NLRP3-IN-75 exhibits superior efficacy in acute peritonitis, diabetic kidney disease and IBD models .

HY-P5724

Nv-CATH	Bacterial	Infection
Nv-CATH is an antibacterial peptide of frog origin. Nv-CATH has broad-spectrum antibacterial activity against gram-positive and gram-negative bacteria. Nv-CATH significantly protects mice from fatal infections caused by Staphylococcus aureus. Nv-CATH protects mice from bacterial infection through antimicrobial immunoregulatory duality .

HY-126898

5-LO/mPGES1-IN-1	Lipoxygenase PGE synthase	Inflammation/Immunology
5-LO/mPGES1-IN-1 (Compound 16) is a dual inhibitor of microsomal prostaglandin E2 synthase-1 (mPGES-1) and 5-lipoxygenase (5-LO). IC₅₀ values are 0.3 and 0.4 μM, respectively. 5-LO/mPGES1-IN-1 has anti-inflammatory activity .

HY-19628A

OD36 hydrochloride	RIP kinase TGF-β Receptor	Inflammation/Immunology
OD36hydrochloride is a RIPK2 inhibitor with an IC₅₀ of 5.3 nM. OD36 hydrochloride is a macrocyclic inhibitor with potent binding to the ALK2 kinase ATP pocket. OD36 hydrochloride shows ALK2-directed activity with K_Ds of 37 nM .

HY-19628

OD36	RIP kinase TGF-β Receptor	Inflammation/Immunology
OD36 is a RIPK2 inhibitor with an IC₅₀ of 5.3 nM. OD36 is a macrocyclic inhibitor with potent binding to the ALK2 kinase ATP pocket. OD36 shows ALK2-directed activity with K_Ds of 37 nM .

HY-109593

BMS-813160 1 Publications Verification	CCR	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
BMS-813160 is a potent and selective CCR2/5 dual antagonist. BMS-813160 binds with CCR2 and CCR5 with IC₅₀s of 6.2 and 3.6 nM, respectively. BMS-813160 can be used for the research of inflammation .

HY-B0466A

Cloxacillin	Beta-lactamase Antibiotic Bacterial	Infection Inflammation/Immunology Cancer
Cloxacillin is an orally active antibacterial agent and β-lactamase inhibitor with an IC₅₀ of 0.04 µM. Cloxacillin can suppress the *S. aureus-induced inflammatory response by inhibiting the activation of MAPKs, NF-кB* and NLRP3-related proteins .

HY-173596

SNT-8370	VAP-1 Glutathione Peroxidase	Inflammation/Immunology
SNT-8370 is an orally active inhibitor of VAP-1 (IC₅₀: 10 nM) and myeloperoxidase (MPO) (IC₅₀: 17 nM), with >100-1000 fold more potency for VAP-1 and MPO versus other mammalian (per)oxidases. SNT-8370 inhibits MPO-mediated LDL lipid peroxidation. SNT-8370 inhibits leukocyte infiltration in lung injury models of acute inflammation. SNT-8370 is an anti-inflammatory agent, and can be used for research of inflammatory disorders .

HY-B0466

Cloxacillin sodium monohydrate 3 Publications Verification	Beta-lactamase Bacterial Antibiotic	Infection Inflammation/Immunology Cancer
Cloxacillin sodium monohydrate is an orally active antibacterial agent and β-lactamase inhibitor with an IC₅₀ of 0.04 µM. Cloxacillin sodium monohydrate can suppress the *S. aureus-induced inflammatory response by inhibiting the activation of MAPKs, NF-кB* and NLRP3-related proteins .

HY-B0466B

Cloxacillin sodium 3 Publications Verification	Beta-lactamase Bacterial Antibiotic	Infection Inflammation/Immunology Cancer
Cloxacillin sodium is an orally active antibacterial agent and β-lactamase inhibitor with an IC₅₀ of 0.04 µM. Cloxacillin sodium can suppress the *S. aureus-induced inflammatory response by inhibiting the activation of MAPKs, NF-кB* and NLRP3-related proteins .

HY-B0466BR

Cloxacillin (sodium) (Standard)	Beta-lactamase Bacterial Antibiotic	Infection Inflammation/Immunology Cancer
Cloxacillin (sodium) (Standard) is the analytical standard of Cloxacillin (sodium). This product is intended for research and analytical applications. Cloxacillin sodium is an orally active antibacterial agent and β-lactamase inhibitor with an IC50 of 0.04 μM. Cloxacillin sodium can suppress the S. aureus-induced inflammatory response by inhibiting the activation of MAPKs, NF-кB and NLRP3-related proteins .

HY-B0466R

Cloxacillin (sodium monohydrate) (Standard)	Beta-lactamase Bacterial Antibiotic	Infection Inflammation/Immunology Cancer
Cloxacillin (sodium monohydrate) (Standard) is the analytical standard of Cloxacillin (sodium monohydrate). This product is intended for research and analytical applications. Cloxacillin sodium monohydrate is an orally active antibacterial agent and β-lactamase inhibitor with an IC₅₀ of 0.04 μM. Cloxacillin sodium monohydrate can suppress the S. aureus-induced inflammatory response by inhibiting the activation of MAPKs, NF-кB and NLRP3-related proteins .

HY-148258

GDC-2394	NOD-like Receptor (NLR) Interleukin Related Caspase	Inflammation/Immunology
GDC-2394 is an orally active and selective NLRP3 inhibitor, and also inhibits IL-1β with IC₅₀s of 0.4 μM (human IL-1β) and 0.1 μM (mouse IL-1β). GDC-2394 inhibits NLRP3-induced caspase-1 activity without inhibiting NLRC4-dependent inflammasome activation .

HY-N1431

Tabersonine 1 Publications Verification	NOD-like Receptor (NLR) Apoptosis Cytochrome P450 NF-κB PI3K Akt CDK Caspase Interleukin Related p38 MAPK	Inflammation/Immunology Cancer
Tabersonine is a selective, orally active NLRP3 inhibitor. Tabersonine directly binds to the NACHT domain of NLRP3, inhibiting its ATPase activity and oligomerization, thereby blocking ASC spot formation and caspase-1 activation, and reducing the release of pro-inflammatory cytokines such as IL-1β. Tabersonine also inhibits K63-linked ubiquitination of TRAF6, blocking NF-κB, PI3K/Akt, and p38 MAPK signaling pathways. Tabersonine can inhibit inflammatory responses, induce apoptosis of liver cancer cells through mitochondrial pathways and death receptor pathways, reduce mitochondrial membrane potential, promote cytochrome c release, and activate caspase proteins. Tabersonine is mainly used in the study of NLRP3-driven inflammatory diseases (such as acute lung injury, sepsis, peritonitis) and tumors such as liver cancer .

HY-N1431A

Tabersonine hydrochloride	NOD-like Receptor (NLR) Apoptosis Cytochrome P450 NF-κB PI3K Akt CDK Caspase Interleukin Related p38 MAPK	Neurological Disease Inflammation/Immunology
Tabersonine hydrochloride is a selective, orally active NLRP3 inhibitor. Tabersonine hydrochloride directly binds to the NACHT domain of NLRP3, inhibiting its ATPase activity and oligomerization, thereby blocking ASC spot formation and caspase-1 activation, and reducing the release of pro-inflammatory cytokines such as IL-1β. Tabersonine hydrochloride also inhibits K63-linked ubiquitination of TRAF6, blocking NF-κB, PI3K/Akt, and p38 MAPK signaling pathways. Tabersonine hydrochloride can inhibit inflammatory responses, induce apoptosis of liver cancer cells through mitochondrial pathways and death receptor pathways, reduce mitochondrial membrane potential, promote cytochrome c release, and activate caspase proteins. Tabersonine hydrochloride is mainly used in the study of NLRP3-driven inflammatory diseases (such as acute lung injury, sepsis, peritonitis) and tumors such as liver cancer .

HY-100897

Sulodexide	Thrombin	Cardiovascular Disease
Sulodexide is an orally active mixture of glycosaminoglycans composed of low molecular weight heparin (80%) and dermatan sulfate (20%). Sulodexide exhibits antithrombotic activity through interaction with antithrombin III (AT III) and heparin cofactor II (HC II), and inhibition of thrombin formation. Sulodexide exhibits profibrinolytic activity through release of tissue plasminogen activator (tPA). Sulodexide exhibits endothelial protective and anti-inflammatory effect, ameliorates chronic venous disease .

Cat. No.	Product Name	Target	Research Area